Early trial aims to tame tough cancers with Two-Pronged attack
NCT ID NCT06545682
Summary
This early-stage study is testing the safety and best dose of a two-drug combination (alpelisib and pembrolizumab) for patients with advanced breast cancer or melanoma that has spread. It aims to see if this combo can help control the disease, including in cases where cancer has spread to the brain. The main goal is to find a dose that is safe enough for future, larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.